Characterisation of patients with systemic lupus erythematosus (N=1073)
| Sociodemographic and SLE related factors | |
| Age, 31 December 2020 | 50.67 (14.89) |
| Female | 942 (87.79) |
| Age at disease onset | 37.23 (14.36) |
| Disease duration, years | 12.89 (6.23) |
| SLE manifestations and comorbidities | |
| Cutaneous | 914 (85.18) |
| Musculoskeletal | 424 (39.51) |
| Renal | 296 (27.59) |
| Haematological | 797 (74.28) |
| Serositis | 116 (10.81) |
| Neurological | 119 (11.09) |
| Variable | Number (%) | Missing |
| Serology and lab | ||
| ANA positivity by any test | 1073 (100.0) | 0 |
| ANA positivity, IFA | 680 (87.97) | 300 |
| Anti-dsDNA, ELISA | 510 (53.01) | 111 |
| Anti-dsDNA IFA | 418 (79.02) | 544 |
| Anti-Smith | 81 (9.70) | 238 |
| Anti-Ro | 356 (35.96) | 83 |
| Anti-La | 205 (20.85) | 90 |
| Cardiolipin IgG, ≥2 positive tests | 250 (24.58) | 56 |
| Cardiolipin IgM, ≥2 positive tests | 168 (19.42) | 208 |
| Beta 2 glycoprotein 1 IgG, ≥2 positive tests | 201 (23.73) | 226 |
| Beta 2 glycoprotein 1 IgM, ≥2 positive tests | 144 (18.85) | 309 |
| Positive PTT ratio, ≥2 tests | 192 (33.22) | 495 |
| Positive RVVT ratio, ≥2 tests | 191 (34.23) | 515 |
| LAC status (positive PTT and/or RVVT ratio) | 232 (38.41) | 469 |
| aPL positivity | 413 (40.37) | 50 |
| C3 below normal range | 539 (50.75) | 11 |
| C3 below normal range, 2020 | 127 (20.32) | 448 |
| C4 below normal range | 341 (32.11) | 11 |
| C4 below normal range, 2020 | 72 (11.56) | 450 |
| Urine protein/creatinine ratio≥0.5 mg/mg | 155 (32.43) | 595 |
| 24-hours urine protein≥500 mg/24 hours | 189 (28.64) | 413 |
| Treatment patterns | ||
| HCQ use, ever | 1073 (100.0) | |
| Immunosuppressant use, ever | 448 (41.75) | |
| Biologics use, ever | 119 (11.09) | |
| GC use, ever | 803 (74.84) | |
| HCQ use, 2020 | 724 (67.47) | |
| Immunosuppressant use, 2020 | 194 (18.08) | |
| Biologics use, 2020 | 57 (5.31) | |
| GC use, 2020 | 330 (30.75) | |
| GC, mean daily dose since diagnosis | ||
| 0–≤5 mg/day | 870 (81.08) | |
| >5–≤7.5 mg/day | 111 (10.34) | |
| >7.5 mg/day | 92 (8.57) | |
Continuous variables are presented as mean (SD), categorical variables are presented as number (%).
ANA, antinuclear antibody; aPL, antiphospholipid; C3, complement 3; C4, complement 4; dsDNA, double-stranded DNA; GC, glucocorticoids; HCQ, hydroxychloroquine; IFA, immunofluorescence assay; Ig, immunoglobulin; LAC, lupus anticoagulant; mg, milligram; PTT, partial thromboplastin time; RVVT, Russel viper venom time; SLE, systemic lupus erythematosus.